[Clinical management of cardiogenic shock].
D000138:Acidosis / Q000188:drug therapy; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000188:drug therapy; D001639:Bicarbonates / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004562:Electrocardiography; D005342:Fibrinolysis; D005934:Glucagon / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006326:Heart Auscultation; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy; D010100:Oxygen / Q000627:therapeutic use; D012121:Respiration, Artificial; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000628:therapy*; D014690:Venous Pressure
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D001639:Bicarbonates; D004071:Digitalis Glycosides; D005938:Glucocorticoids; D005934:Glucagon; D010100:Oxygen
Die klinische Behandlung des kardiogenen Schocks.